Methods of treating transthyretin (TTR) mediated amyloidosis

A method of treating polyneuropathy in a patient with hereditary transthyretin-mediated amyloidosis (hATTR), the method comprising administering a dose of a TTR siRNA with lipid excipients to the patient,

• wherein the TTR siRNA consists of a sense strand consisting of SEQ ID NO:1 and an antisense strand consisting of SEQ ID NO:2;
• and
• the lipid excipients consist of DLin-MC3-DMA ((6Z, 9Z, 28Z, 31Z)-heptatriaconta-6, 9, 28, 31-tetraen-19-yl-4-(dimethylamino) butanoate), DSPC ((1,2-Distearoyl-sn-Glycero-3-Phosphocholine), cholesterol, and PEG2000-C-DMG (((R)-methoxy-PEG2000-carbamoyl-di-O-myristyl-sn-glyceride) in isotonic phosphate buffered saline;
• wherein the dose is 0.3 mg siRNA per kg body weight, and the TTR siRNA with lipid excipients is administered via IV infusion once every three weeks, and the patient receives a premedication before infusion to reduce the risk of infusion-related reactions.